Morgan Stanley
LENZ

Morgan Stanley’s LENZ Therapeutics LENZ Stock Holding History

Morgan Stanley’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Sell
472,995
-175,853
-27% -$1.42M ﹤0.01% 4668
2026
Q1 		$5.94M Buy
648,848
+415,466
+178% +$5.84M ﹤0.01% 4009
2025
Q4 		$3.73M Sell
233,382
-62,837
-21% -$1.83M ﹤0.01% 4398
2025
Q3 		$13.8M Sell
296,219
-289,136
-49% -$10.6M ﹤0.01% 3254
2025
Q2 		$17.2M Buy
585,355
+396,611
+210% +$10.8M ﹤0.01% 2961
2025
Q1 		$4.85M Buy
188,744
+96,460
+105% +$2.38M ﹤0.01% 3953
2024
Q4 		$2.66M Buy
92,284
+41,806
+83% +$1.27M ﹤0.01% 4497
2024
Q3 		$1.2M Sell
50,478
-15,697
-24% -$348K ﹤0.01% 4942
2024
Q2 		$1.14M Buy
66,175
+38,964
+143% +$681K ﹤0.01% 4875
2024
Q1 		$608K Sell
27,211
-2,043
-7% -$42.5K ﹤0.01% 5221
2023
Q4 		$537K Buy
29,254
+8,402
+40% +$139K ﹤0.01% 5260
2023
Q3 		$362K Buy
20,852
+10,578
+103% +$184K ﹤0.01% 5310
2023
Q2 		$187K Sell
10,274
-18,915
-65% -$378K ﹤0.01% 5677
2023
Q1 		$501K Buy
29,189
+24,146
+479% +$391K ﹤0.01% 5254
2022
Q4 		$117K Buy
5,043
+568
+13% +$13.2K ﹤0.01% 5909
2022
Q3 		$100K Sell
4,475
-98,446
-96% -$2.35M ﹤0.01% 6080
2022
Q2 		$1.98M Buy
102,921
+22,545
+28% +$503K ﹤0.01% 4551
2022
Q1 		$2.87M Sell
80,376
-19,393
-19% -$1.21M ﹤0.01% 4240
2021
Q4 		$8.68M Buy
99,769
+40,660
+69% +$3.37M ﹤0.01% 3099
2021
Q3 		$6.78M Buy
59,109
+21,466
+57% +$3.18M ﹤0.01% 3359
2021
Q2 		$8.1M Buy
+37,643
New +$6.56M ﹤0.01% 3242

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Morgan Stanley's LENZ Position: Q2 2026 in Review

Morgan Stanley reduced its LENZ Therapeutics (LENZ) stake by 27% in Q2 2026, selling an estimated $1.42M and leaving 472,995 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #4668.

Morgan Stanley first reported a position in LENZ in Q2 2021 and has held it in 21 quarters since. The position peaked at $17.2M in Q2 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Morgan Stanley held 472,995 shares of LENZ Therapeutics worth $2.69M as of Q2 2026.
  • Morgan Stanley sold 175,853 LENZ Therapeutics shares in Q2 2026, an estimated $1.42M.
  • LENZ Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4668 holding.
  • Morgan Stanley first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Morgan Stanley's LENZ Therapeutics position peaked at $17.2M in Q2 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.